A: Photograph shows the DNF plann ed fo r reconstruction ofthe large circular defect. Note that the height of the free edge is much greater than the height of the defect itself B: The mobilized flap is seen prior to rotation. Note the extensive undermining in the correct avascular plane. C: Early cosmesis is excellent. The nasal incisions are located primarily along the alar crease and gla bellarfrown lines. There is no evidence offlap tension or elevation of the alar cartilage.
A 67-year-old man presented with a I-year history of a slowly enlarging lesion on the tip of his nose. The 2.0 x I.S-cm infiltrative , pearly lesion extended from the left nasal supratip to the left alar groove. No evidence of tran snasal involvement or ulceration was observed. Pathologic examination of a small punch biopsy specimen revealed that the lesion was a nodular basal cell carcinoma. The patient was offered Mohs ' micrographic excision, but he refused, citing the lengthiness of the procedure and the possible need for a second-stage delayed reconstruction. Moreover, his medical history was sign ificant for severe cardiovascular disease, and he was therefore worried about the possible cardiac complications of prolonged surgery and/or anesthesi a. He ultimately agreed to local excision with single-stage recon struction under local anesthesia and intravenous sedation.
The surgical resection created a full-thicknes s defect that involved the left nasal lobule (figure, A). After considering all reconstructive options, we chose to use a dorsal nasal flap (DNF) . The patient 's surgical margin s were all negative, and he recovered uneventfully with excellent cosmetic results.
The DNF was first described by Rieger in 1967 .' When used as a rotational flap, the DNF requ ires that most or all 
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ADVERSE REACTIONS
The incidence of common adverse reactions is based upon two U.S. and five non-U.S. controlled clini cal trials in 1,526patients [110fe males and239males lessthan18yearsof age,and635 femal esand542mal esl Byearsofage and older) treated with RHINOCORTAOUA Nasal Sprayat doses upto400 meg once dail y for 3-6weeks. Th etable belowdescribesadverse eventsoccurring atan incidenceof 2%or greater and morecommonamong RHINOCORT AQUA NasalSpray-treated pati ents than in placebo-treated patientsincontroll ed cli nical tri als.Theoverall incidence of adverse eventswas similar betweenRHINOCORT AOUA andplacebo. • The defect should be no larger than 2.5 em, which will help minimiz e distortion of the surrounding anatomy.
• The flap design should be of sufficient height at the intended free edge relative to the defect to acco unt for the shortening associate d with flap rotation.
• The flap should include larger pedicle vesse ls (axia l branch of the angular artery) to help ensure its survival.
• A liberal dose of I% lidocaine with epinephrine should be injected into areas of intended dissection to prevent patient discomfort and to help minimi ze bleeding. (Caution should be exercised in the area of the flap pedicle.)
• Incision and dissection of the flap should be made in an avascular plane adjacent to the perichondrium. Extensive underminin g of the flap is the key to tension-free rotation (figure, BV There are several adva ntages to using a DNF :
• The entire procedure can be completed with local anesthesia and light sedation.
• Because nasal skin is used to close the wound, the cosmetic result in term s of skin color, texture, and thickness is excellent.
• Incisions can often be made in natural skin lines and creases (figure, C) .
Circle 117 on Reader Service Card
SerenocemThl was designed specifically for non-weight bearing applications in otologic surge ry including:
• Reconstruction of the ossicular chain where cement can be used to repair the bony ossicles in their normal position • Acoustic meatal wall reconstruction • Cementation of cochlear implant electro des The disadvantages of the DNF include limited flap mobility and the possibilit y, although minimal, of ischemia that could result in a defect much larger than the original.
In summa tion, the DNF is a useful reconstructi ve option for closing nasal defects in a single-stage procedure under local anesthes ia, and cosmetic outcomes are excellent. It is especially useful in patients with medical comorbidities that preclud e the use of general anesthesia, as in this case .
